<DOC>
	<DOCNO>NCT01851824</DOCNO>
	<brief_summary>This open-label , multicenter , 3-period , fixed-sequence study evaluate effect multiple dose vemurafenib pharmacokinetics single dose acenocoumarol participant BRAFV600 mutation-positive metastatic malignancy . Participants receive single dose acenocoumarol 4 mg orally Day 1 Day 23 , vemurafenib 960 mg orally twice daily Days 4-26 . After completion pharmacokinetic assessment Day 26 , eligible participant option continue treatment vemurafenib part extension study ( GO28399 [ NCT01739764 ] ) .</brief_summary>
	<brief_title>A Study Effect Vemurafenib Pharmacokinetics Acenocoumarol Patients With BRAFV600 Mutation-Positive Metastatic Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Adult patient , 1870 year age Patients either unresectable Stage IIIc IV BRAFV600 mutationpositive metastatic melanoma malignant BRAFV600 mutationpositive tumor type acceptable standard treatment option Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Full recovery major surgery significant traumatic injury least 14 day prior first dose study treatment Adequate hematologic end organ function Female patient childbearing potential male patient female partner childbearing potential must agree use 2 effective method contraception define protocol course study least 6 month completion study treatment Prior treatment vemurafenib BRAF inhibitor within 42 day Day 1 Prior anticancer therapy within 28 day ( 6 week nitrosureas mitocyn C , 14 day hormonal therapy kinase inhibitor ) first dose study treatment Day 1 Palliative radiotherapy within 2 week prior first dose study treatment Day 1 Experimental therapy within 4 week prior first dose study treatment Day 1 History clinically significant cardiac pulmonary dysfunction , include current uncontrolled Grade &gt; /=2 hypertension unstable angina Current Grade &gt; /=2 dyspnea hypoxia need oxygen supplementation History myocardial infarction within 6 month prior first dose study treatment Active central nervous system lesion ( i.e . participant radiographically unstable , symptomatic lesion ) History bleed coagulation disorder Allergy hypersensitivity vemurafenib acenocoumarol formulation History malabsorption condition would interfere enteral absorption study treatment Participants VKORC1 mutation ( 1639G &amp; # 8594 ; A , 1173C &amp; # 8594 ; T ) either one allele ( heterozygous ) two allele ( homozygous ) Participants CYP2C9*3 mutation either one allele ( heterozygous ) two allele ( homozygous ) History clinically significant liver disease ( include cirrhosis ) , current alcohol abuse , active hepatitis B hepatitis C virus infection Human immunodeficiency virus ( HIV ) infection require antiretroviral treatment , AIDSrelated illness Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>